FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to application of neramexane or its pharmaceutically acceptable salt in a combination with a glutamate release inhibitor for treating neurodegenerative disorders, and also emotional instability and pseudobulbar affect associated with neurodegenerative disorders. The glutamate release inhibitor is selected from riluzole and its pharmaceutically acceptable salts. The neurodegenerative disorder represents a motor neuron disease.
EFFECT: therapy with the combined neramexane and riluzole provides relieved progression of the neurodegenerative disease which surpasses a relief effect induced by therapy with riluzole only.
35 cl, 4 tbl, 2 ex
| Title |
Year |
Author |
Number |
| USE OF SULPHATE SALTS OF N-(3-(4-(3-(DIISOBUTYLAMINO)PROPYL)PIPERAZIN-1-YL)PROPYL)-1N-BENZO[D]IMIDAZOL-2-AMINE AND THEIR SOLVATES FOR TREATMENT OF MOTOR NEURON DISEASES AND NEUROMUSCULAR DISEASES |
2021 |
- Callizot, Noelle
- Estrella, Cecilia
- Barrier, Mathieu
- Verwaerde, Philippe
|
RU2814327C1 |
| PHARMACEUTICAL COMPOSITION FOR INHIBITING AUTOPHAGY OF MOTOR NEURONS AND USE THEREOF |
2012 |
- Lin Shinn-Zong
- Harn Horng
- Chiou Tzyy-Wen
- Hsuen Kuo-Wei
|
RU2585372C1 |
| THERAPEUTIC AGENTS AGAINST NEURODEGENERATIVE DISEASES |
2017 |
|
RU2756519C2 |
| UROKINASE INHIBITORS ADMINISTRATION FOR TREATMENT AND/OR PREVENTION OF NEUROPATHOLOGICAL DISEASES |
2006 |
- Lorentsl' Shtefan
- Shmaliks Vol'Fgang
|
RU2410087C2 |
| COMPOSITIONS AND METHODS OF THEIR USE FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) |
2019 |
|
RU2804764C2 |
| USE OF BENZOATE FOR TREATMENT OF DISORDERS OF CENTRAL NERVOUS SYSTEM |
2017 |
- Tsai, Guochuan Emil
- Chen, Hong-Jung
- Hsu, Wei-En
- Chang, Weiju
- Huang, Jing-Jia
|
RU2780450C2 |
| TREATMENT OF NEUROLOGICAL DYSFUNCTION BY USING FRUCTOPYRANOSE AND ERYTHROPOIETIN SULFAMATES |
2002 |
- Plata-Salaman Karlos
- Smit-Svintoski Virdzhinija
|
RU2317086C2 |
| PHARMACEUTICAL COMPOSITIONS FOR NEURAL DISORDER TREATMENT, CONTAINING DEXTROMETHORPHANE AND QUINIDINE |
2003 |
- Jakatan Geral'D
- Berg Dzhejms
- Poup Laura E.
- Smit Richard A.
|
RU2341265C2 |
| THERAPEUTIC AGENTS FOR NEURODEGENERATIVE DISEASES |
2018 |
|
RU2763425C2 |
| 1-[[2-(2,2,2-TRIFLUORETHOXY)PYRIDE-4-YL]METHYL]UREA DERIVATIVES AS KCNQ POTENTIATORS |
2020 |
- Szekeres, Helen, Jane
- Whatton, Maria, Ann
- Williams, Andrew, Caerwyn
|
RU2790174C1 |
